应用Ig/TCR重排监测儿童淋巴瘤微小残留病  

Using Ig/TCR gene rearrangements to monitor minimal residual disease in pediatric lymphoma

作　　者：邢艳平(综述)[1] 张永红(审校)[1] 

机构地区：[1]首都医科大学附属北京儿童医院血液病中心,100045

出　　处：《白血病．淋巴瘤》2010年第11期695-698,共4页Journal of Leukemia & Lymphoma

基　　金：北京市卫生局首都医学发展科研基金（2007-1030）

摘　　要：淋巴瘤微小残留病（MRD）的准确检测对判断预后、评价疗效、监测复发和指导治疗具有十分重要的意义.免疫球蛋白（Ig）/T细胞受体（TCR）重排可以作为肿瘤特异性PCR标志用于MRD的监测.BIOMED-2策略是欧洲协作组制定的标准化多重PCR反应方法.MRD的检测可以通过实时荧光定量PCR的方法完成.对Ig/TCR重排监测儿童淋巴瘤MRD的原理及其相关研究进展进行了综述.Detection of minimal residual disease （MRD） exactly for lymphoma is important for estimating prognosis, assessing response, monitoring relapse and instructing treatment. Immunoglobulin （Ig）/T-cell receptor （TCR） gene rearrangements can be used as special tumorous markers for MRD testing by PCR.BIOMED-2 strategy is a method about multiplex PCR reaction designed by European Collaborative Organization. Monitoring MRD can be completed by real-time quantitative PCR. In this paper, the principle and research progress related to the application of IG/TCR in MRD detection are mainly reviewed for lymphoma in children.

关 键 词：Ig/TCR重排 肿瘤 残余 实时定量PCR 

分 类 号：R733.71[医药卫生—肿瘤]